Rocket Pharmaceuticals (RCKT) Consolidated Net Income: 2016-2025
Historic Consolidated Net Income for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$52.0 million.
- Rocket Pharmaceuticals' Consolidated Net Income rose 24.15% to -$52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.2 million, marking a year-over-year increase of 7.45%. This contributed to the annual value of -$266.8 million for FY2024, which is 4.13% down from last year.
- Per Rocket Pharmaceuticals' latest filing, its Consolidated Net Income stood at -$52.0 million for Q3 2025, which was up 26.89% from -$71.1 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Consolidated Net Income registered a high of -$33.8 million during Q2 2021, and its lowest value of -$71.9 million during Q2 2024.
- Moreover, its 3-year median value for Consolidated Net Income was -$64.2 million (2023), whereas its average is -$64.5 million.
- The largest annual percentage gain for Rocket Pharmaceuticals' Consolidated Net Income in the last 5 years was 27.53% (2021), contrasted with its biggest fall of 71.22% (2021).
- Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Consolidated Net Income stood at -$43.9 million in 2021, then slumped by 55.43% to -$68.3 million in 2022, then climbed by 7.86% to -$62.9 million in 2023, then rose by 2.20% to -$61.5 million in 2024, then climbed by 24.15% to -$52.0 million in 2025.
- Its Consolidated Net Income stands at -$52.0 million for Q3 2025, versus -$71.1 million for Q2 2025 and -$63.5 million for Q1 2025.